Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: Where do we go?

Reviews in Medical Virology

Volumn 22, Issue 2, 2012, Pages 88-105

  Olthof, Nadine C ^a   Straetmans, Jos M J A A ^a   Snoeck, Robert ^b   Ramaekers, Frans C S ^a   Kremer, Bernd ^a   Speel, Ernst Jan M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVE; ALPHA INTERFERON; ARTIFICIAL ZINC FINGER; BETA INTERFERON; CELL PENETRATING PEPTIDE; CETUXIMAB; CIDOFOVIR; CYCLIN D1; GAMMA INTERFERON; HEPARAN; IMMUNOMODULATING AGENT; LOPINAVIR; PROBENECID; PROTEIN E6; PROTEIN E7; PROTEIN P14; PROTEIN P16; PROTEIN P53; RITONAVIR; TELOMERASE REVERSE TRANSCRIPTASE; THIOREDOXIN; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VIMENTIN; VIRUS DNA; VIRUS PROTEIN; WART VIRUS VACCINE; ZINC FINGER PROTEIN;

ALCOHOL ABUSE; ANGIOGENESIS; ANOGENITAL SQUAMOUS CELL CARCINOMA; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DRUG SCREENING; GENE PRODUCT; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; IMMUNE RESPONSE; IMMUNOMODULATION; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING; METASTASIS; MORBIDITY; NEPHROTOXICITY; NONHUMAN; ORAL SQUAMOUS CELL CARCINOMA; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; ROBOTICS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TOBACCO DEPENDENCE; TONSIL; TRANSORAL ROBOTIC SURGERY; UTERINE CERVICAL SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; VIRION; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS REPLICATION; WART VIRUS;

ANTIVIRAL AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; OROPHARYNX; PALATINE TONSIL; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 84857983556     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.714     Document Type: Review

References (192)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010; 127: 2893-2917. DOI: 10.1002/ijc.25516
2. Johnson N, Franceschi S, Ferlay J, et al. Oral Cavity and Oropharynx. In: Pathology and Genetics Head and Neck Tumours, Barnes L, Eveson J, Reichart P, Sidransky D (ed). IARC Press: Lyon, 2005; 163-208.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: a Cancer Journal for Clinicians 2008; 58: 71-96.
4. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110: 1429-1435. DOI: 10.1002/cncr.22963
5. Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Research 2003; 63: 1727-1730.
6. Haughey BH, Gates GA, Arfken CL, et al. Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Annals of Otology, Rhinology and Laryngology 1992; 101: 105-112.
7. Pattle SB, Farrell PJ. The role of Epstein-Barr virus in cancer. Expert Opinion on Biological Therapy 2006; 6: 1193-1205. DOI: 10.1517/14712598.6.11.1193
8. Carvalho AL, Nishimoto IN, Califano JA, et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. International Journal of Cancer 2005; 114: 806-816. DOI: 10.1002/ijc.20740
9. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. International Journal of Cancer 2003; 107: 394-400. DOI: 10.1002/ijc.11389
10. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. International Journal of Cancer 2007; 121: 1813-1820. DOI: 10.1002/ijc.22851
11. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. Journal of Clinical Oncology 2006; 24: 2606-2611. DOI: 10.1200/JCO.2006.06.1291
12. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? International Journal of Cancer 2009; 125: 362-366. DOI: 10.1002/ijc.24339
13. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27. DOI: 10.1016/j.virol.2004.03.033
14. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-79. DOI: 10.1016/j.virol.2010.02.002
15. World Health Organization. Human papillomaviruses: IARC Monographs on the evaluation of carcinogenic risks to humans. International Agency for Research on Cancer: Lyon, 2007
16. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England Journal of Medicine 2003; 348: 518-527.
17. Hiller T, Poppelreuther S, Stubenrauch F, et al. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiology, Biomarkers & Prevention 2006; 15: 1262-1267. DOI: 10.1158/1055-9965.EPI-05-0778
18. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010; 118: 471-493. DOI: 10.1111/j.1600-0463.2010.02618.x
19. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecologic Oncology 2010; 118: S12-17. DOI: 10.1016/j.ygyno.2010.04.004
20. Yoon CS, Kim KD, Park SN, et al. alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP. Biochemical and Biophysical Research Communications 2001; 283: 668-673. DOI: 10.1006/bbrc.2001.4838
21. Horvath CA, Boulet GA, Renoux VM, et al. Mechanisms of cell entry by human papillomaviruses: an overview. Virology Journal 2010; 7: 11. DOI: 10.1186/1743-422X-7-11
22. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews. Cancer 2002; 2: 342-350. DOI: 10.1038/nrc798
23. McMurray HR, McCance DJ. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. Journal of Virology 2003; 77: 9852-9861. DOI: 10.1128/JVI.77.18.9852-9861.2003
24. Liu X, Dakic A, Zhang Y, et al. HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 18780-18785. DOI: 10.1073/pnas.0906357106
25. Funk JO, Waga S, Harry JB, et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes & Development 1997; 11: 2090-2100. DOI: 10.1101/gad.11.16.2090
26. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of CDK2. Genes & Development 1997; 11: 2101-2111. DOI: 10.1101/gad.11.16.2101
27. Zerfass-Thome K, Zwerschke W, Mannhardt B, et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996; 13: 2323-2330.
28. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. Journal of Virology 1995; 69: 7791-7799.
29. Ziegert C, Wentzensen N, Vinokurova S, et al. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 2003; 22: 3977-3984. DOI: 10.1038/sj.onc.1206629
30. Park IS, Chang X, Loyo M, et al. Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prevention Research (Philadelphia, Pa.) 2011; 4: 207-217. DOI: 10.1158/1940-6207.CAPR-10-0147
31. Stanley MA. Human papillomavirus vaccines. Reviews in Medical Virology 2006; 16: 139-149. DOI: 10.1002/rmv.498
32. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii human papillomavirus cohort study. Cancer Research 2008; 68: 8813-8824. DOI: 10.1158/0008-5472.CAN-08-1380
33. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002; 55: 244-265.
34. Hopman AH, Smedts F, Dignef W, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. The Journal of Pathology 2004; 202: 23-33. DOI: 10.1002/path.1490
35. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Research 2008; 68: 307-313. DOI: 10.1158/0008-5472.CAN-07-2754
36. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. International Journal of Cancer 2009; 124: 1626-1636. DOI: 10.1002/ijc.24116
37. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer 2007; 121: 621-632. DOI: 10.1002/ijc.22527
38. Cricca M, Morselli-Labate AM, Venturoli S, et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecologic Oncology 2007; 106: 549-557. DOI:10.1016/j.ygyno.2007.05.004
39. Guo M, Sneige N, Silva EG, et al. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Modern Pathology 2007; 20: 256-266. DOI:10.1038/modpathol.3800737
40. Sigurdsson K, Taddeo FJ, Benediktsdottir KR, et al. HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. International Journal of Cancer 2007; 121: 2682-2687. DOI: 10.1002/ijc.23034
41. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. International Journal of Cancer 2008; 122: 2656-2664. DOI: 10.1002/ijc.23458
42. Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. International Journal of Cancer 2002; 102: 152-158. DOI: 10.1002/ijc.10669
43. Koskinen WJ, Chen RW, Leivo I, et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. International Journal of Cancer 2003; 107: 401-406. DOI: 10.1002/ijc.11381
44. Ukpo OC, Moore EJ, Smith DI. Human papillomavirus and oropharyngeal cancer. The New England Journal of Medicine 2007; 357: 1156-1157; author reply 1157-1158.
45. Frisch M, Biggar RJ. Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas. Lancet 1999; 354: 1442-1443. DOI:10.1016/S0140-6736(99)92824-6
46. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 2001; 344: 1125-1131.
47. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. European Journal of Cancer Prevention 2000; 9: 433-437.
48. Syrjanen K, Syrjanen S, Lamberg M, et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. International Journal of Oral Surgery 1983; 12: 418-424. DOI: 10.1016/S0300-9785(83)80033-7
49. Klussmann JP, Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 2875-2884.
50. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. International Journal of Cancer 2001; 93: 232-235. DOI: 10.1002/ijc.1313
51. D'Souza G, Agrawal Y, Halpern J, et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. Journal of Infectious Diseases 2009; 199: 1263-1269. DOI: 10.1086/597755
52. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiology, Biomarkers & Prevention 2005; 14: 467-475.
53. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute 2000; 92: 709-720.
54. McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head & Neck 1998; 20: 250-265. DOI: 10.1002/(SICI)1097-0347(199805)20:3<250::AID-HED11>3.0.CO;2-O
55. Chen R, Aaltonen LM, Vaheri A. Human papillomavirus type 16 in head and neck carcinogenesis. Reviews in Medical Virology 2005; 15: 351-363. DOI: 10.1002/rmv.471
56. Mooren JJ, Hopman AHN, Ramaekers FCS, et al. Chromosome stability in tonsillar squamous cell carcinoma is associated with HPV and a favorable prognosis (O191). Oral Oncology Supplement 2009; 3: 119-120. DOI: 10.1016/j.oos.2009.06.276
57. Klingenberg B, Hafkamp HC, Haesevoets A, et al. p16 INK4A overexpression is frequently detected in tumour-free tonsil tissue without association with HPV. Histopathology 2010; 56: 957-967. DOI: 10.1111/j.1365-2559.2010.03576.x
58. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. Journal of the National Cancer Institute 2003; 95: 1772-1783. DOI: 10.1093/jnci/djg107
59. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. International Journal of Cancer 2007; 121: 2465-2472. DOI: 10.1002/ijc.22980
60. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS 2010; 118: 510-519. DOI: 10.1111/j.1600-0463.2010.02624.x
61. Marur S, D'Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology 2010; 11: 781-789. DOI: 10.1016/S1470-2045(10)70017-6
62. Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21: 1510-1517. DOI: 10.1038/sj/onc/1205214
63. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. Journal of Clinical Oncology 2006; 24: 736-747. DOI: 10.1200/JCO.2004.00.3335
64. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. American Journal of Pathology 2003; 162: 747-753. DOI:10.1016/S0002-9440(10)63871-0
65. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. Journal of Clinical Oncology 2009; 27: 6213-6221. DOI: 10.1200/JCO.2009.23.1670
66. Hafkamp HC, Mooren JJ, Claessen SM, et al. P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Modern Pathology 2009; 22: 686-698. DOI:10.1038/modpathol.2009.23
67. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. International Journal of Cancer 2007; 120: 1731-1738. DOI: 10.1002/ijc.22355
68. Klussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clinical Cancer Research 2009; 15: 1779-1786. DOI: 10.1158/1078-0432.CCR-08-1463
69. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. Journal of Clinical Oncology 2008; 26: 3128-3137. DOI: 10.1200/JCO.2007.12.7662
70. Kim SH, Koo BS, Kang S, et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. International Journal of Cancer 2007; 120: 1418-1425. DOI: 10.1002/ijc.22464
71. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. International Journal of Radiation Oncology, Biology, and Physics 2009; 74: 553-561. DOI: 10.1016/j.ijrobp.2009.02.015
72. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nature Reviews. Cancer 2011; 11: 9-22. DOI: 10.1038/nrc2982
73. Grimminger CM, Danenberg PV. Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. European Archives of Oto-Rhino-Laryngology 2011; 268: 5-16. DOI: 10.1007/s00405-010-1369-x
74. Jung AC, Briolat J, Millon R, et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. International Journal of Cancer 2010; 126: 1882-1894. DOI: 10.1002/ijc.24911
75. Rincon-Orozco B, Halec G, Rosenberger S, et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Research 2009; 69: 8718-8725. DOI: 10.1158/0008-5472.CAN-09-0550
76. Martinez I, Wang J, Hobson KF, et al. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. European Journal of Cancer 2007; 43: 415-432. DOI: 10.1016/j.ejca.2006.09.001
77. Slebos RJ, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clinical Cancer Research 2006; 12: 701-709. DOI: 10.1158/1078-0432.CCR-05-2017
78. Schlecht NF, Burk RD, Adrien L, et al. Gene expression profiles in HPV-infected head and neck cancer. The Journal of Pathology 2007; 213: 283-293. DOI: 10.1002/path.2227
79. Wald AI, Hoskins EE, Wells SI, et al. Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head & Neck 2010; 33: 504-512. DOI: 10.1002/hed.21475
80. Melle C, Ernst G, Winkler R, et al. Proteomic analysis of human papillomavirus-related oral squamous cell carcinoma: identification of thioredoxin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue. Proteomics 2009; 9: 2193-2201. DOI: 10.1002/pmic.200800882
81. Clinical practice guidelines in oncology - Head and Neck Cancers. [18-01-2011]
82. Moore EJ, Henstrom DK, Olsen KD, et al. Transoral resection of tonsillar squamous cell carcinoma. Laryngoscope 2009; 119: 508-515. DOI: 10.1002/lary.20124
83. Park YM, Lee JG, Lee WS, et al. Feasibility of transoral lateral oropharyngectomy using a robotic surgical system for tonsillar cancer. Oral Oncology 2009; 45: e62-66. DOI:10.1016/j.oraloncology.2009.02.012
84. Haigentz M, Jr., Silver CE, Corry J, et al. Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. European Archives of Oto-Rhino-Laryngology 2009; 266: 1845-1855. DOI: 10.1007/s00405-009-1109-2
85. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiotherapy and Oncology 2007; 85: 156-170. DOI: 10.1016/j.radonc.2007.04.002
86. Sobin L, Gosposarowics M, Wittekind C. Head and neck. In: TNM Classification of malignant Tumors, O'Sullivan B (ed). Wiley-Blackwell: West-Sussex, 2010; 17-50.
87. Lindel K, Beer KT, Laissue J, et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-813.
88. Ringstrom E, Peters E, Hasegawa M, et al. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clinical Cancer Research 2002; 8: 3187-3192.
89. Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? International Journal of Cancer 2010; 126: 1256-1262. DOI: 10.1002/ijc.24842
90. Fallai C, Perrone F, Licitra L, et al. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. International Journal of Radiation Oncology, Biology, and Physics 2009; 75: 1053-1059. DOI: 10.1016/j.ijrobp.2008.12.088
91. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2009; 27: 1992-1998. DOI: 10.1200/JCO.2008.20.2853
92. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute 2008; 100: 261-269. DOI: 10.1093/jnci/djn011
93. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clinical Cancer Research 2010; 16: 1226-1235. DOI: 10.1158/1078-0432.CCR-09-2350
94. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. The New England Journal of Medicine 2010; 363: 24-35.
95. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiotherapy and Oncology 2010; 95: 371-380. DOI: 10.1016/j.radonc.2010.04.022
96. Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Current Opinion in Oncology 2009; 21: 201-205. DOI: 10.1097/CCO.0b013e328329ab64
97. Marur S. Paclitaxel, cisplatin, and cetuximab followed by cetuximab and intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery. NCT01084083, 2010.
98. Centres for disease control and prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and Mortal Weekly Report 2010; 59: 626-629.
99. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommendations and Reports 2007; 56: 1-24.
100. Centres for disease control and prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and Mortality Weekly Report 2010; 59: 630-632.
101. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecologic Oncology 2008; 110: S18-25. DOI:10.1016/j.ygyno.2008.06.027
102. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314. DOI:10.1016/S0140-6736(09)61248-4
103. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26years. Journal of Infectious Diseases 2009; 199: 926-935. DOI: 10.1086/597307
104. Jagu S, Kwak K, Garcea RL, et al. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 2010; 28: 4478-4486. DOI: 10.1016/j.vaccine.2010.04.039
105. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26: 6844-6851. DOI: 10.1016/j.vaccine.2008.09.073
106. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines 2009; 5: 696-704.
107. Munoz N, Manalastas R, Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45years: a randomised, double-blind trial. Lancet 2009; 373: 1949-1957. DOI: 10.1016/S0140-6736(09)60691-7
108. Hung CF, Ma B, Monie A, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opinion on Biological Therapy 2008; 8: 421-439. DOI:10.1517/14712598.8.4.421
109. Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecologic Oncology 2007; 106: 453-460. DOI:10.1016/j.ygyno.2007.04.038
110. Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. Journal of Virology 2008; 82: 1968-1979. DOI:10.1128/JVI.02343-07
111. Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. The Lancet Oncology 2009; 10: 975-980. DOI: 10.1016/S1470-2045(09)70227-X
112. Wu A, Zeng Q, Kang TH, et al. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Therapy 2011; 18: 304-312. DOI:10.1038/gt.2010.151
113. Edelman M. MAGE-A3/HPV 16 vaccine for squamous cell carcinoma of the head and neck. NCT00257738, 2005.
114. Edelman M. Four doses of MAGE vaccine for patients with squamous cell carcinoma of the head and neck. NCT00704041, 2009.
115. Mak T, Saunders M. Cytokines and cytokine receptors. In: The immune response - basic and clinical principles, Picknett T, Lebedeva V (ed). Elsevier Academic Press: Oxford, 2006; 464-517.
116. Beglin M, Melar-New M, Laimins L. Human papillomaviruses and the interferon response. Journal of Interferon & Cytokine Research 2009; 29: 629-635. DOI:10.1089/jir.2009.0075
117. Nees M, Geoghegan JM, Hyman T, et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. Journal of Virology 2001; 75: 4283-4296. DOI: 10.1128/JVI.75.9.4283-4296.2001
118. de Jong A, van der Burg SH, Kwappenberg KM, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Research 2002; 62: 472-479.
119. Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Research 2003; 63: 636-641.
120. Yang J, Pu YG, Zeng ZM, et al. Interferon for the treatment of genital warts: a systematic review. BMC Infectious Diseases 2009; 9: 156. DOI:10.1186/1471-2334-9-156
121. Gonzalez-Sanchez JL, Martinez-Chequer JC, Hernandez-Celaya ME, et al. Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus. Obstetrics and Gynecology 2001; 97: 621-624.
122. Syed TA, Ahmadpour OA. Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. International Journal of STD and AIDS 1998; 9: 769-772.
123. Bornstein J, Pascal B, Zarfati D, et al. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. International Journal of STD and AIDS 1997; 8: 614-621.
124. Yliskoski M, Syrjanen K, Syrjanen S, et al. Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial. Gynecologic Oncology 1991; 43: 55-60.
125. Chang YE, Pena L, Sen GC, et al. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. Journal of Virology 2002; 76: 8864-8874. DOI: 10.1128/JVI.76.17.8864-8874.2002
126. Herdman MT, Pett MR, Roberts I, et al. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 2006; 27: 2341-2353. DOI: 10.1093/carcin/bgl172
127. Saikia P, Fensterl V, Sen GC. The inhibitory action of P56 on select functions of E1 mediates interferon's effect on human papillomavirus DNA replication. Journal of Virology 2010; 84: 13036-13039. DOI: 10.1128/JVI.01194-10
128. Terenzi F, Saikia P, Sen GC. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO Journal 2008; 27: 3311-3321. DOI: 10.1038/emboj.2008.241
129. Lace MJ, Anson JR, Klingelhutz AJ, et al. Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. Carcinogenesis 2009; 30: 1336-1344.
130. Gerein V, Rastorguev E, Gerein J, et al. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Annals of Otology, Rhinology and Laryngology 2005; 114: 463-471.
131. De Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antiviral Research 2005; 67: 56-75. DOI: 10.1016/j.antiviral.2005.05.001
132. Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002; 21: 2334-2346. DOI: 10.1038/sj/onc/1205006
133. Andrei G, Snoeck R, Schols D, et al. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncology Research 2000; 12: 397-408.
134. Andrei G, Snoeck R, Piette J, et al. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncology Research 1998; 10: 523-531.
135. Spanos WC, El-Deiry M, Lee JH. Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity. Annals of Otology, Rhinology and Laryngology 2005; 114: 840-846.
136. Sirianni N, Wang J, Ferris RL. Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncology 2005; 41: 423-428. DOI: 10.1016/j.oraloncology.2004.11.003
137. Park J, Kommareddi P, Nair T, et al. Cidofovir modulates HPV E6 and E7 as well as p53, Rb and MDM2 in HPV16 naturally transformed head and neck squamous cell carcinoma and enhances chemosensitivity to cisplatin. Proceedings of the American Association for Cancer Research. Orlando, Fl, USA. 2011.
138. Donne AJ, Hampson L, He XT, et al. Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease. Antiviral Therapy 2009; 14: 939-952.
139. Donne AJ, Rothera MP, Homer JJ. Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. International Journal of Pediatric Otorhinolaryngology 2008; 72: 939-944. DOI: 10.1016/j.ijporl.2008.04.003
140. Wolf DL, Rodriguez CA, Mucci M, et al. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. Journal of Clinical Pharmacology 2003; 43: 43-51. DOI: 10.1177/0091270002239705
141. Snoeck R, Noel JC, Muller C, et al. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). Journal of Medical Virology 2000; 60: 205-209. DOI: 10.1002/(SICI)1096-9071(200002)60:2<205::AID-JMV16>3.0.CO;2-8
142. Van Pachterbeke C, Bucella D, Rozenberg S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecologic Oncology 2009; 115: 69-74. DOI: 10.1016/j.ygyno.2009.06.042
143. Snoeck R, Bossens M, Parent D, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clinical Infectious Diseases 2001; 33: 597-602. DOI: 10.1086/322593
144. Tristram A, Fiander A. Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecologic Oncology 2005; 99: 652-655. DOI:10.1016/j.ygyno.2005.07.127
145. Petersen BL, Buchwald C, Gerstoft J, et al. An aggressive and invasive growth of juvenile papillomas involving the total respiratory tract. Journal of Laryngology and Otology 1998; 112: 1101-1104.
146. Deutsch E. Cidofovir in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer who are receiving chemotherapy and radiation therapy. NCT00811408, 2008.
147. Chen XZ, Zhu KJ, Xu Y, et al. RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clinical and Experimental Dermatology 2010; 35: 509-515. DOI: 10.1111/j.1365-2230.2009.03624.x
148. Butz K, Ristriani T, Hengstermann A, et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-5945. DOI: 10.1038/sj.onc.1206894
149. Rampias T, Sasaki C, Weinberger P, et al. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. Journal of the National Cancer Institute 2009; 101: 412-423. DOI: 10.1093/jnci/djp017
150. Sima N, Wang W, Kong D, et al. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 2008; 13: 273-281. DOI: 10.1007/s10495-007-0163-8
151. Yamato K, Yamada T, Kizaki M, et al. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Therapy 2008; 15: 140-153. DOI:10.1038/sj.cgt.7701118
152. Putral LN, Bywater MJ, Gu W, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Molecular Pharmacology 2005; 68: 1311-1319. DOI: 10.1124/mol.105.014191
153. Merlano M, Russi E, Benasso M, et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Annals of Oncology 2011; 22: 712-717. DOI: 10.1093/annonc/mdq412
154. Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. International Journal of Radiation Oncology, Biology, and Physics 2003; 56: 922-928. DOI:10.1016/S0360-3016(03)00209-8
155. Kummel S, Heidecke H, Brock B, et al. Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study. Gynäkologisch-Geburtshilfliche Rundschau 2008; 48: 94-100. DOI: 10.1159/000119032
156. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 2005; 5: 749-759. DOI: 10.1038/nri1703
157. Molinolo AA, Amornphimoltham P, Squarize CH, et al. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncology 2009; 45: 324-334. DOI: 10.1016/j.oraloncology.2008.07.011
158. Straetmans JM, Olthof N, Mooren JJ, et al. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 2009; 119: 1951-1957. DOI: 10.1002/lary.20593
159. Stenner M, Yosef B, Huebbers CU, et al. Nuclear translocation of beta-catenin and decreased expression of epithelial cadherin in human papillomavirus-positive tonsillar cancer: an early event in human papillomavirus-related tumour progression? Histopathology 2011; 10.1111/j.1365-2559.2011.03805.x
160. Soo K. Study of post-op adjuvant concurrent chemo-RT with or without nimotuzumab for head & neck cancer. NCT00957086, 2009.
161. Schmidtke G, Holzhutter HG, Bogyo M, et al. How an inhibitor of the HIV-I protease modulates proteasome activity. Journal of Biological Chemistry 1999; 274: 35734-35740. DOI: 10.1074/jbc.274.50.35734
162. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antiviral Therapy 2006; 11: 813-825.
163. Mino T, Hatono T, Matsumoto N, et al. Inhibition of DNA replication of human papillomavirus by artificial zinc finger proteins. Journal of Virology 2006; 80: 5405-5412. DOI:10.1128/JVI.01795-05
164. Mino T, Mori T, Aoyama Y, et al. Cell-permeable artificial zinc-finger proteins as potent antiviral drugs for human papillomaviruses. Archives of Virology 2008; 153: 1291-1298. DOI: 10.1007/s00705-008-0125-7
165. Lepique AP, Daghastanli KR, Cuccovia IM, et al. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clinical Cancer Research 2009; 15: 4391-4400. DOI: 10.1158/1078-0432.CCR-09-0489
166. Visser J, Nijman HW, Hoogenboom BN, et al. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clinical and Experimental Immunology 2007; 150: 199-209. DOI: 10.1111/j.1365-2249.2007.03468.x.
167. Chuang CM, Hoory T, Monie A, et al. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine 2009; 27: 684-689. DOI: 10.1016/j.vaccine.2008.11.042
168. Mahto M, Nathan M, O'Mahony C. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. International Journal of STD and AIDS 2010; 21: 8-16. DOI:10.1258/ijsa.2009.009309
169. Lucker GP, Speel EJ, Creytens DH, et al. Differences in imiquimod treatment outcome in two patients with bowenoid papulosis containing either episomal or integrated human papillomavirus 16. The Journal of Investigative Dermatology 2007; 127: 727-729. DOI:10.1038/sj.jid.5700578
170. Johnson JA, Gangemi JD. Alpha interferon augments cidofovir's antiviral and antiproliferative activities. Antimicrobial Agents and Chemotherapy 2003; 47: 2022-2026. DOI: 10.1128/AAC.47.6.2022-2026.2003
171. Benson J, Bramlage B, Fitzgerald K, et al. dsRNA compositions and methods for treating HPV infection. Alnylam Pharmaceuticals Inc. 2011.
172. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science (London, England) 2006; 110: 525-541. DOI:10.1042/CS20050369
173. Ganguly N, Parihar SP. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. Journal of Biosciences 2009; 34: 113-123.
174. Hafkamp HC, Manni JJ, Speel EJ. Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Oto-Laryngologica 2004; 124: 520-526. DOI 10.1080/00016480310016893
175. Hamid NA, Brown C, Gaston K. The regulation of cell proliferation by the papillomavirus early proteins. Cellular and Molecular Life Sciences 2009; 66: 1700-1717. DOI:10.1042/CS20050369
176. Beaudenon S, Praetorius F, Kremsdorf D, et al. A new type of human papillomavirus associated with oral focal epithelial hyperplasia. The Journal of Investigative Dermatology 1987; 88: 130-135.
177. Cuberos V, Perez J, Lopez CJ, et al. Molecular and serological evidence of the epidemiological association of HPV 13 with focal epithelial hyperplasia: a case-control study. Journal of Clinical Virology 2006; 37: 21-26. DOI:10.1016/j.jcv.2006.04.003
178. Altavilla G, Staffieri A, Busatto G, et al. Expression of p53, p16INK4A, pRb, p21WAF1/CIP1, p27KIP1, cyclin D1, Ki-67 and HPV DNA in sinonasal endophytic Schneiderian (inverted) papilloma. Acta Oto-Laryngologica 2009; 129: 1242-1249.
179. Syrjanen KJ. HPV infections in benign and malignant sinonasal lesions. Journal of Clinical Pathology 2003; 56: 174-181. DOI: 10.1136/jcp.56.3.174
180. Goon P, Sonnex C, Jani P, et al. Recurrent respiratory papillomatosis: an overview of current thinking and treatment. European Archives of Oto-Rhino-Laryngology 2008; 265: 147-151. DOI: 10.1007/s00405-007-0546-z
181. Stamataki S, Nikolopoulos TP, Korres S, et al. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head & Neck 2007; 29: 155-162. DOI: 10.1002/hed.20491
182. Campisi G, Giovannelli L, Arico P, et al. HPV DNA in clinically different variants of oral leukoplakia and lichen planus. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2004; 98: 705-711. DOI:10.1016/j.tripleo.2004.04.012
183. Yang SW, Lee YS, Chen TA, et al. Human papillomavirus in oral leukoplakia is no prognostic indicator of malignant transformation. Cancer Epidemiology 2009; 33: 118-122. DOI: 10.1016/j.canep.2009.05.003
184. Barzon L, Militello V, Pagni S, et al. Distribution of human papillomavirus type in the anogenital tract of females and males. Journal of Medical Virology 2010; 82: 1424-1430. DOI: 10.1002/jmv.21733
185. Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. British Journal of Cancer 2006; 94: 171-175. DOI: 10.1038/sj.bjc.6602915
186. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. Journal of the National Cancer Institute 2006; 98: 303-315. DOI: 10.1093/jnci/djj067
187. Severson J, Evans TY, Lee P, et al. Human papillomavirus infections: epidemiology, pathogenesis, and therapy. Journal of Cutaneous Medicine and Surgery 2001; 5: 43-60.
188. Ashinoff R, Li JJ, Jacobson M, et al. Detection of human papillomavirus DNA in squamous cell carcinoma of the nail bed and finger determined by polymerase chain reaction. Archives of Dermatology 1991; 127: 1813-1818.
189. Kreuter A, Gambichler T, Pfister H, et al. Diversity of human papillomavirus types in periungual squamous cell carcinoma. British Journal of Dermatology 2009; 161: 1262-1269. DOI: 10.1111/j.1365-2133.2009.09343.x
190. Li W, Thompson CH, O'Brien CJ, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. International Journal of Cancer 2003; 106: 553-558. DOI: 10.1002/ijc.11261
191. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004; 5: 311-316. DOI: 10.1016/S1535-6108(04)00090-X
192. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. International Journal of Cancer 2003; 104: 336-344. DOI: 10.1002/ijc.10960